Spero Therapeutics (NASDAQ: SPRO) COO receives RSUs, option and tax sales

Rhea-AI Filing Summary

Spero Therapeutics Chief Operating Officer Timothy Keutzer reported new equity awards and related tax sales of common stock. On February 2, 2026, he received 68,000 restricted stock units that vest in four equal annual installments beginning February 2, 2027, contingent on continued service. He also received a stock option for 137,000 shares at $2.23 per share, vesting 25% on February 2, 2027, with the rest vesting in 36 monthly installments.

To cover tax withholding from RSU vesting, Keutzer had automatic “sell to cover” transactions of 18,891 shares at $2.20, 24,224 shares at $2.14, and 3,471 shares at $2.24, which the filing states were not discretionary trades. After these transactions, he directly owned 761,158 shares of common stock and 137,000 stock options.

Insider Trade Summary

Net Seller: 46,586 shares ($101,175)

Net Sell 5 txns

Insider Keutzer Timothy

Role Chief Operating Officer

Sold 46,586 shs ($101K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,471	$2.24	$8K
Sale	Common Stock	24,224	$2.14	$52K
Grant/Award	Stock Option (Right to Buy)	137,000	$0.00	--
Grant/Award	Common Stock	68,000	$0.00	--
Sale	Common Stock	18,891	$2.20	$42K

Holdings After Transaction: Common Stock — 761,158 shares (Direct); Stock Option (Right to Buy) — 137,000 shares (Direct)

Footnotes (1)

1. Consists of restricted stock units ("RSUs") granted to Reporting Person under Issuer's 2017 Stock Incentive Plan. Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 2, 2027, subject to the Reporting Person's continued service through the applicable vesting date. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. The shares underlying this option vest as to 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Keutzer Timothy

(Last) (First) (Middle)

C/O SPERO THERAPEUTICS, INC.

675 MASSACHUSETTS AVENUE, 14TH FLOOR

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Spero Therapeutics, Inc. [ SPRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		A		68,000(1)	A	$0.00	807,744	D
Common Stock	02/02/2026		S(2)		18,891(2)	D	$2.2	788,853	D
Common Stock	02/03/2026		S(2)		24,224(2)	D	$2.14	764,629	D
Common Stock	02/04/2026		S(2)		3,471(2)	D	$2.24	761,158	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.23	02/02/2026		A		137,000		(3)	02/02/2026	Common Stock	137,000	$0	137,000	D

Explanation of Responses:

1. Consists of restricted stock units ("RSUs") granted to Reporting Person under Issuer's 2017 Stock Incentive Plan. Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 2, 2027, subject to the Reporting Person's continued service through the applicable vesting date.

2. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

3. The shares underlying this option vest as to 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ Maegan Deare, Attorney-in-Fact for Timothy Keutzer	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Spero Therapeutics (SPRO) COO Timothy Keutzer report?

Timothy Keutzer reported receiving 68,000 RSUs and a stock option for 137,000 shares, plus automatic sales of 18,891, 24,224, and 3,471 shares to cover tax withholding. After these, he held 761,158 common shares and 137,000 options directly.

How do Timothy Keutzer’s new RSUs at Spero Therapeutics (SPRO) vest?

Keutzer’s 68,000 RSUs vest in four equal annual installments starting February 2, 2027. Each unit converts into one share of common stock upon vesting, and vesting is conditioned on his continued service through each applicable vesting date.

What are the terms of Timothy Keutzer’s new stock option at Spero Therapeutics (SPRO)?

The stock option covers 137,000 Spero Therapeutics common shares at an exercise price of $2.23. It vests 25% on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments, subject to his continued service.

Were Timothy Keutzer’s recent Spero Therapeutics (SPRO) share sales discretionary trades?

The filing states the reported sales were required to cover tax withholding on RSU vesting and were executed automatically through a sell-to-cover mechanism. It specifically notes these transactions do not represent discretionary trading decisions by Keutzer.

How many Spero Therapeutics (SPRO) shares does COO Timothy Keutzer own after these transactions?

Following the reported grants and tax-related sales, Keutzer beneficially owned 761,158 shares of Spero Therapeutics common stock directly. He also held 137,000 stock options, which are subject to the vesting schedule described in the filing.

What is the significance of the tax-related sell-to-cover transactions for Spero Therapeutics (SPRO) COO?

The sell-to-cover transactions indicate shares were sold solely to satisfy tax withholding from RSU vesting. This structure allows taxes to be paid without separate cash outlay and, as disclosed, does not reflect discretionary portfolio management by the executive.